Biocon unifies with Biocon Biologics to establish a single global biopharma entity

New Delhi: Biocon Limited, an innovation-led global biopharmaceutical company, has announced a major strategic step to fully integrate Biocon Biologics Limited (BBL) as a wholly owned subsidiary, subject to regulatory approvals.

To oversee this transition, the company has formed a Governance Council chaired by Kiran Mazumdar-Shaw, alongside a Transition and Integration Management Committee led by Shreehas Tambe, CEO and Managing Director of Biocon Biologics.

This decision follows a comprehensive review conducted by the Strategy Committee, established in May 2025, which explored multiple strategic pathways for BBL, including the possibility of an IPO or a merger with Biocon Limited. After considering strategic alignment, industry trends, shareholder value, and long-term growth potential, the Committee concluded that full integration—accompanied by the acquisition of minority stakes—represents the most efficient and value-accretive direction for the business.

Under the proposed plan, Biocon Limited will acquire the remaining shares of Biocon Biologics from Serum Institute Life Sciences, Tata Capital Growth Fund II and Activ Pine LLP through a share swap of 70.28 Biocon shares for every 100 BBL shares, valuing Biocon Biologics at USD 5.5 billion based on a Biocon share price of INR 405.78. Biocon will also acquire the residual stake held by Mylan Inc. (Viatris) for a total consideration of USD 815 million, which includes a cash component of USD 400 million, supplemented by a share swap equivalent to 61.70 Biocon shares for every 100 BBL shares at the same share price. The swap ratios have been approved by the Board following independent valuations conducted by EY.

To support this transaction, the Board has also approved raising up to INR 4,500 crore (USD 500 million) through a Qualified Institutional Placement, subject to shareholder approval. The capital raised will primarily fund the cash payment due to Viatris. The integration is expected to be completed by March 31, 2026, and is set to streamline the company’s structure by bringing together its generics and biosimilars businesses under one unified platform. This realignment is intended to strengthen Biocon’s global presence in diabetes, oncology, and immunology—therapeutic areas that represent nearly 40% of global pharmaceutical revenues. With capabilities spanning biosimilar insulins and generic versions of complex peptides, including GLP-1s, Biocon is well positioned to serve the rapidly expanding global ‘diabesity’ market.

During the transition period, Siddharth Mittal and Shreehas Tambe will continue in their current roles as CEO and Managing Director of Biocon Limited and Biocon Biologics Limited, respectively. Once the integration is complete and all approvals are secured, Shreehas Tambe will assume the role of CEO and Managing Director of the combined company, while Kedar Upadhye will take over as Chief Financial Officer. Siddharth Mittal will transition into a broader leadership role within the Biocon Group.

Commenting on the initiative, Kiran Mazumdar-Shaw, Executive Chairperson of Biocon Limited, said: “The integration of Biocon Biologics into Biocon marks the next chapter in our evolution. Strategically, Biocon will be among the few companies globally to offer both biosimilars and generics at scale. As the only company providing biosimilar insulins and generic GLP-1 peptides, we are uniquely positioned to address the needs of people living with diabetes. Together with our combined oncology and immunology portfolios, this integration creates a differentiated offering aimed at solving some of the world’s most pressing healthcare challenges. I am pleased that Shreehas Tambe will lead the Transition and Integration Committee and, subject to requisite approvals, take over as CEO and Managing Director of the unified business. His 28 years of experience within the Biocon Group will be pivotal as we advance our mission to make life-saving medicines affordable and accessible worldwide.”

This integration will enable Biocon to leverage the combined strengths of its biosimilars and generics operations across more than 120 countries. Biocon Biologics is currently ranked among the top five biosimilar players globally by revenue, with ten commercial products across key markets, while Biocon’s generics business offers more than ninety products worldwide.